Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jul;65(7):399-405.
doi: 10.1369/0022155417708186. Epub 2017 May 22.

Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3

Affiliations
Comparative Study

Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3

Jessica Tracht et al. J Histochem Cytochem. 2017 Jul.

Abstract

Grading of pancreatic neuroendocrine tumors (pNETs) is currently based on mitotic rate and Ki67 proliferation index. Phosphohistone-H3 (PHH3) is an effective marker for mitosis that has been proposed to use in grading various NETs. It remains unclear which method more accurately predicts grade and clinical outcome. Cases of pNET were evaluated using immunohistochemical stains for Ki67 and PHH3. In addition, each case was evaluated for necrosis, lymphovascular invasion, and perineural invasion and compared with stage. R project statistical analysis was used for comparisons. Sixty-three cases were included in the study including 29 males and 34 females (M:F 0.9) with a median age of 59 years (ranging 34-84). There was not a significant discrepancy in the stratification of tumor grades for Ki67 and PHH3. PHH3 significantly predicted lymph node metastasis ( p=0.041). Necrosis correlated with overall survival ( p=0.017). The results suggest that PHH3 is an effective marker for determining mitotic activity and can be used alternative to Ki67. In addition, necrosis may be included in the reporting of pNET as it may play a prognostic role. Larger scale studies are warranted to understand the biology and behavior of these tumors.

Keywords: Ki67; PHH3; mitosis; neuroendocrine tumor; pancreas.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Grade 1 pancreatic neuroendocrine tumor (A) with Ki67 with a proliferation index of <2% (B) and phosphohistone-H3 (PHH3) showing no mitotic activity (C). The H&E stain of grade 2 pancreatic neuroendocrine tumor with two mitotic figures (arrows; D) showing increased Ki67 with a proliferation index of 3–20% (E) and increased mitotic activity by PHH3 (three mitoses per high power field; F). High-grade (grade 3) tumor (G) with >20% proliferation rate via Ki67 (H) and increased mitotic figures highlighted by the PHH3 stain (I). The scale size is the same for all the figures. Scale, 90 µm.
Figure 2.
Figure 2.
Scatter plots for phosphohistone-H3 (PHH3) (A) and Ki67 (B) stratified by the mitotic counts; within each subfigure, the x-axis is the sample index, the y-axis is PHH3/Ki67, and the highlighted is the corresponding mitotic counts (n=63).

Similar articles

Cited by

References

    1. Yang Z, Tang LH, Klimstra DS. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. Semin Diagn Pathol. 2013;30:186–96. - PubMed
    1. Ries LAG. Cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2007.
    1. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691–703. - PubMed
    1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18, vii. - PubMed
    1. Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010.

Publication types